🇺🇸 FDA
Patent

US 6673559

Met proto-oncogene and a method for predicting breast cancer progression

expired A61KA61K38/193

Quick answer

US patent 6673559 (Met proto-oncogene and a method for predicting breast cancer progression) held by The United States of America as Represented by the Government of the Department of Health and Human Services expires Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America as Represented by the Government of the Department of Health and Human Services
Grant date
Tue Jan 06 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K38/193